Skip to main content
Premium Trial:

Request an Annual Quote

Acolyte and Berthold Technologies Sign Marketing Alliance for Rapitect Assays

NEW YORK, June 1 (GenomeWeb News) - Berthold Technologies GmbH & Co. KG will distribute Acolyte's BacLite RapiTect range of enumeration assays in Europe and U.S. under a marketing agreement, Acolyte Biomedica said today.

 

The assay range uses adenylate kinase as a highly sensitive marker of viable cells. The technology, originally developed by the UK Ministry of Defence, is up to 100 times more sensitive than standard ATP bioluminescence and up to one million times more sensitive than optical measurements. Acolyte has exclusive licenses to the technology for commercial exploitation in life sciences research.

 

Financial details were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.